Having trouble accessing articles? Reset your cache.

Xarelto rivaroxaban: Phase III data

The open-label, international Phase III EINSTEIN-DVT trial in >3,400 patients showed that oral rivaroxaban was non-inferior to current standard therapy (initial Lovenox enoxaparin followed by a vitamin K

Read the full 283 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE